With its recent data drop for an oligonucleotide candidate, Dyne Therapeutics signals it may become a frontrunner in this ...

Write better code with AI Security ...

LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington’s ...

Data from DELIVER and ACHIEVE Clinicals Trial to be Presented - - Presentation on ACHIEVE Trial in DM1 and Company Symposium to Feature Data on the Use of Splicing Correction as a Prognostic Biomarker ...

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) has been assigned an average recommendation of “Buy” from the thirteen ratings firms that are currently covering the stock, Marketbeat Ratings ...

Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for ...

candidate for myotonic dystrophy type 1 (DM1), and del-brax for facioscapulohumeral muscular dystrophy (FSHD). All three candidates are based on the same TfR1-targeting antibody component.

The presentations will include data on the safety and efficacy of the DYNE-251 treatment for Duchenne muscular dystrophy and DYNE-101 for myotonic dystrophy type 1, along with insights into using ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.